

DUKE UNIVERSITY MEDICAL CENTER

CURRICULUM VITAE

for

Permanent Record

and the

Appointments and Promotions Committee

Last Updated: January 11, 2017

Name: John Alexander Bartlett, M.D.

Primary academic appointment: Department of Internal Medicine

Present academic rank and title: Professor of Medicine

Date and rank of first Duke faculty appointment: July 1, 1987 - Associate in Medicine

Medical Licensure: Licensed, National Board of Medical Examiners, 1982
Licensed, State of North Carolina, 1982
License Number 26488
Licensed, Medical Board of Tanganyika, 2004

Specialty certification and dates: Certified, American Board of Internal Medicine, Internal Medicine, 1984
Certified, American Board of Internal Medicine, Infectious Diseases, 1988

Education:	Place	Date	Degree
High School	Pittsford High School	1973	
College	Harvard University	1977	AB cum laude
Graduate or Professional School	University of Virginia	1981	MD

Professional training and academic career:

1981-1982 Intern, Duke University Medical Center
1982-1984 Resident, Duke University Medical Center
1983 Assistant Chief Resident, Duke University Medical Center
1984 Chief Resident, Durham County General Hospital
1985-1987 Fellow, Division of Infectious Diseases, Duke University Medical Center
1987-1988 Associate in Medicine, Division of Infectious Diseases, Duke University Medical Center
1987-2004 Director, Duke University Medical Center Adult Infectious Diseases Clinic
1989-1996 Assistant Professor of Medicine, Division of Infectious Diseases, Duke University Medical Center
1990-present Principal Investigator, Duke University Adult AIDS Clinical Trials Unit
1992-present Director of Clinical Research, Duke University Center for AIDS Research
1993-2003 Associate Director, Clinical Research Unit, Duke University Medical Center
1996-present Senior Fellow, Duke University Center for Health Policy Research and Education
1996-2001 Associate Professor of Medicine, Division of Infectious Diseases, Duke University Medical Center
2001-present Professor of Medicine, Division of Infectious Diseases, Duke University Medical Center
2003-present Fellow, Health Inequalities Program, Sanford Institute of Public Policy, Duke University
2004-present Professor of Nursing, Duke University Medical Center
2004-2008 Principal Investigator, International Studies of AIDS-associated Co-infections
2004-present Director of Research, AIDS International Training Research Program

2005-present	Co-Director, Duke University Center for AIDS Research
2006-present	Professor of Medicine, Kilimanjaro Christian Medical College
2008-present	Associate Director for Research, Duke University Global Health Institute
2010-2011	Director of Post-doctoral Fellowship Training, Duke Global Health Institute
2010-present	Director, HIV-associated Malignancies Research Training Program
2012-present	Professor of Global Health
2013-present	Member, Duke Cancer Institute

Publications:

1. Refereed journals:

Bartlett JA, Gaillard RK, Joklik WK. Sequencing of supercoiled plasmid DNA. *Biotechniques*. 4:208-210, 1986.

Cohen JI, Bartlett JA, Corey GR. Extraintestinal Salmonellosis. *Medicine*. 66:349-388, 1987.

Bartlett JA, Joklik WK. The sequence of the reovirus serotype 3 L3 genome segment which encodes the major core protein lambda 1. *Virology*. 167:31-37, 1988.

Bartlett JA. HIV therapeutics: an emerging science. *JAMA* 260:3051-3052, 1988.

Weiner JR, Bartlett JA, Joklik WK. The sequences of reovirus serotype 3 genome segments M1 and M3 encoding the minor protein mu2 and the major non-structural protein muNS, respectively. *Virology*. 169:293-304, 1989.

Shaunak S, Bartlett JA. Zidovudine: Clinical use and complications in treatment. *AIDS Medical Report*. 2:33-39, 1989.

Shaunak S, Bartlett JA. Zidovudine-induced neutropenia: Are we too cautious? *Lancet*. 2:91-92, 1989.

Drew RH, Weller S, Gallis HA, Walmer KA, Bartlett JA, Blum MR. Bioequivalence assessment of Retrovir syrup, solution and capsule formulations in HIV infected patients. *Antimicrobial Agents and Chemotherapy*. 33:1801-1803, 1989.

Tyler DS, Shaunak S, Bartlett JA, Inglehart JD. HIV-1 associated thrombocytopenia: The role of splenectomy. *Annals of Surgery*. 211:211-217, 1990.

Volberding P, Lagakos S, Koch M, Pettinelli C, Myers M, Booth D, Balfour H, Reichman R, Bartlett JA, Hirsch M, Murphy R, Hardy WD, Soeiro R, Fischl M, Bartlett JG, Merigan T, Hyslop N, Richman D, Valentine F, Corey L and the AIDS Clinical Trials Group. Zidovudine in asymptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4 positive cells per cubic millimeter. *New England Journal of Medicine*. 322:941-949, 1990.

Tyler D, Stanley D, Nastala C, Stine K, Austin A, Bartlett J, Lyerly H, Bolognesi D, Weinhold K. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. *Journal of Immunology*. 144:3375-3384, 1990.

Telen MJ, Roberts KB, Bartlett JA. HIV-associated autoimmune hemolytic anemia: Report of a case and review of the literature. *Journal of Acquired Immune Deficiency Syndromes*. 3:933-937, 1990.

Shaunak S, Albright RE, Klotman ME, Henry SC, Bartlett JA, Hamilton JD. Amplification of HIV-1 provirus from cerebrospinal fluid and its correlation with neurological disease. *Journal of Infectious Diseases*. 161:1068-1072, 1990.

Ingram C, Bartlett JA. Simultaneous pneumococcal and pneumocystis pneumonia in patients with the acquired immune deficiency syndrome: Report of two cases. *Southern Medical Journal*. 83:1215-1217, 1990.

- Cameron M, Bartlett J, Gallis H, Waskin H. Manifestations of pulmonary cryptococcosis in patients with acquired immune deficiency syndrome. *Reviews of Infectious Diseases*. 13:64-67, 1991.
- Hersh E, Abrams D, Bartlett J, Brewton G, Galpin J, Gill P, Gorter R, Gottlieb M, Jonikas J, Landesman S, Levine A, Marcel A, Peterson E, Whiteside M, Zahradnik J, Negron C, Boutitie F, Caraux J, Dupuy J, Salmi L. A randomized double-blind placebo-controlled multicenter study of sodium dithiocarb (diethyldithiocarbamate) therapy in patients with ARC and AIDS. *Journal of the American Medical Association*. 265:1538-1544, 1991.
- Shadduck PP, Weinberg JB, Haney AF, Bartlett JA, Langlois AJ, Bolognesi DP, Matthews TJ. Lack of enhancing effect of human anti-HIV-1 antibody on HIV-1 infection of human blood monocytes and peritoneal macrophages. *Journal of Virology*. 65:4309-4316, 1991.
- Stine KC, Tyler DS, Stanley SD, Bartlett JA, Bolognesi DP, Weinhold K. The effect of AZT on *in vitro* lymphokine-activated killer (LAK) activity in human immunodeficiency virus type-1 (HIV-1) infected individuals. *Cellular Immunology*. 136:165-172, 1991.
- Chen C-H, Weinhold KJ, Bartlett JA, MacDougall MJ, Greenberg ML. CD8+ T-lymphocytes mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism. *AIDS Research & Human Retroviruses*. 9:1079-1086, 1993.
- Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR. Correlation of *in vitro* fluconazole resistance of *Candida* isolates in relation to therapy and symptoms in HIV-1 seropositive individuals. *Antimicrobial Agents and Chemotherapy*. 37:2449-2453, 1993.
- Myers SA, Prose NS, Bartlett JA. Progress in the understanding of HIV infection: An overview. *Journal of the American Academy of Dermatology*. 29:1-21, 1993.
- Goodwin SD, Gallis HA, Chow AT, Wong FA, Flor SC, Bartlett JA. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. *Antimicrobial Agents and Chemotherapy*. 38:799-804, 1994.
- Volberding P, Lagakos S, Grimes J, Stein D, Balfour H, Dolin R, Bartlett J, Hirsch M, Phair J, Mitsuyasu R, Fischl M, Soeiro R and the AIDS Clinical Trial Group. The duration of zidovudine benefit in persons with asymptomatic HIV infection: Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. *Journal of the American Medical Association*. 272:437-442, 1994.
- May DB, Drew R, Yedinak J, Bartlett JA. Effect of simultaneous didanosine(DDI) administration on itraconazole absorption in healthy volunteers. *Pharmacotherapy*. 14(5):509-513, 1994.
- Bartlett JA. Early *versus* delayed zidovudine in the management of HIV infection. *Expert Opinions in Investigational Drugs*. 3(8):809-819, 1994.
- Graham CS, Graham BG, Bartlett JA, Heald AE, Schiffman SS. Taste and smell losses in HIV infected patients. *Physiology & Behavior*. 58:287-294, 1995.
- Cohen OJ, Pantaleo G, Holodniy M, Schnittman S, Niu M, Graziosi C, Pavlakis G, Lalezari J, Bartlett JA, Steigbigel RT, Cohen J, Novak R, McMahon D, Fauci AS. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects down regulation of viral replication in lymphoid tissue. *Proceedings of the National Academy of Sciences USA*. 92:6017-6021, 1995.
- Ferrari G, King K, Rathbun K, Packard M, Bartlett JA, Bolognesi D, Weinhold K. Interleukin 7 (IL-7) enhancement of antigen-driven activation/expansion of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte precursors (CTL). *Clinical and Experimental Immunology* 1995;101:239-248.
- Jacobson MA, DeGruttola V, Reddy M, Ardino J-M, Strickland S, Reichman RC, Bartlett JA, Phair JP, Hirsch MS, Collier AC, Soeiro R, Volberding P. The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine. *AIDS*

1995;9:727-734.

Anstey N, Packard M, Stewart L, Graney W, Bartlett JA. Open-label titration study of the safety of RMP-7 in patients with the acquired immune deficiency syndrome. *International Journal of Antimicrobial Agents* 1996;6:183-187.

Cohen OJ, Pantaleo G, Holodniy M, Fox CH, Orenstein JM, Schnittman S, Niu M, Graziosi C, Pavlakis GN, Lalezari J, Bartlett JA, Steigbigel RT, Cohn J, Novak R, McMahon D, Bilello J, Fauci AS. Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on viral load in peripheral blood and lymph nodes. *Journal of Infectious Diseases*. 173:849-856, 1996.

Heald AE, Cox GM, Schell WA, Bartlett JA, Perfect JR. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. *AIDS*. 10:263-268, 1996.

Heald AE, Hsyu P, Yuen G, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in HIV-infected patients with renal dysfunction. *Antimicrobial Agents and Chemotherapy* 40(6):1514-1519, 1996.

Bartlett JA, Benoit SL, Johnson VA, Quinn JB, Sepulveda GE, Ehmann WC, *et al.* Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 1996,125:161-172.

Phillips AN, Eron JJ, Bartlett JA, Rubin M, Johnson J, Price S, *et al.* HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group. *AIDS* 1996,10:859-865.

Heald AE, Hoffman JM, Bartlett JA, Waskin HA. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). *International Journal of STDs and AIDS*. 7:337-346, 1996.

Riddler SA, Wang LH, Bartlett JA, Savina PM, Packard MV, McMahon DK, Blum MR, Dunn JA, Elkins MM, Mellors JW. Safety and pharmacokinetics of 5-chloro-2',3'-dideoxy-3'fluorouridine (935U83) following oral administration of escalating single doses in HIV-infected adults. *Antimicrobial Agents and Chemotherapy*. 40(12):2842-2847, 1996.

Gottfredsson M, Oury T, Bernstein C, Carpenter C, Bartlett JA. Lymphoma of the pituitary gland: An unusual presentation of central nervous system lymphoma in AIDS. *American Journal of Medicine*. 5:563-564, 1996.

Phillips AN, Eron J, Bartlett JA, Gilbert C, Johnson J, Keller A, Hill AM, and the North American Lamivudine HIV Working Group. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. *AIDS*. 11(2):169-175, 1997.

Staszewski S, Hill AM, Bartlett JA, Eron JJ, Katlama C, Johnson J, Sawyer W, McDade H. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. *AIDS*. 11:477-483, 1997.

Bartlett JA, Hullette C. Central nervous system pneumocystosis in the acquired immune deficiency syndrome. *Clinical Infectious Diseases*. 25:82-85, 1997.

Ferrari G, Berend C, Ottinger J, Dodge R, Bartlett J, Toso J, Moody D, Tartaglia J, Cox W, Paoletti E, Weinhold K. Replication -defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: Implications for antigen-specific immunotherapy. *Blood*, (90) 6; 2406-2416, 1997.

Hecht FM, Wheat J, Korzun AH, Hafner R, Skahan KJ, Larsen R, Limjoco MT, Simpson M, Schneider D, Keefer MC, Clark R, Lai KK, Jacobson JM, Squires K, Bartlett JA and Powderly W. Itraconazole maintenance treatment for histoplasmosis in AIDS: A prospective, multicenter trial. *Journal of Immune Deficiency Syndromes and Human Retrovirology*. 16:100-107, 1997.

Tyler DS, Stanley SD, Bartlett JA, Bolognesi DP, Weinhold KJ. Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: A potential strategy for reduction of virus-infected cellular reservoirs. *Journal of Surgical Research* 79:115-120 1998.

Bartlett JA, Berry P, Bockman W, Johnson J, Quinn J, Graham S, DeMasi R, Alexander WJ. A placebo controlled trial of ranitidine in patients with early HIV infection. *Journal of Infectious Diseases* 1998;177:231-234.

Bartlett JA, Berend C, Ottinger J, Tyler D, Petroni G, Petinelli C, Weinhold KJ. Co-administration of zidovudine and interleukin-2 increases absolute CD4+ cells in subjects with Walter Reed stage 2 HIV infection: Results of ACTG protocol 042. *Journal of Infectious Diseases*, 1998;178:1170-1173.

Bartlett JA, Wasserman SS, Hicks CB, Dodge RT, Weinhold KJ, Tacket CO, et al. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative. *AIDS* 1998;12:1291-1300.

Bartlett JA. Strategies of antiretroviral therapy in adults. *The Oncologist* 1998;3:111-118.

Bartlett JA, DeMasi R, Dawson D, Hill A. Variability in the repeated consecutive measurements of plasma HIV RNA in persons on stable nucleoside reverse transcriptase inhibitor or no therapy. *Journal of Infectious Disease* 1998;178:1803-1805.

Haynes BF, Hale L, Weinhold K, Patel D, Liao HX, Bressler P, Jones D, Demarest J, Gebhard-Mitchell K, Haase, Bartlett JA. Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection. *Journal of Clinical Investigation* 103:453-460, 1999.

Moore KHP, Yuen GY, Hussey EK, Pakes GE, Eron JJ, Bartlett JA. Population pharmacokinetics of lamivudine in adult HIV-infected patients enrolled in two phase III clinical trials. *Antimicrobial Agents & Chemotherapy* 43(12): 1999.

Markert ML, Hicks CB, Bartlett JA, Harmon JL, Hale LP, Greenberg ML, et al. Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection. *AIDS Res Hum Retroviruses* 2000;16:403-413.

Nelson CG, Iler MA, Woods CW, Bartlett JA, Fowler VG. Meningococemia in a patient co-infected with Hepatitis C virus and HIV. *Emerging Infectious Diseases* 6(6):646-648, 2000.

Human Immunodeficiency Virus Type 1 RNA level and CD4 Count as Prognostic Markers and Surrogate End Points: A Meta-Analysis. *AIDS Research and Human Retroviruses* 16(12):2000, pp.1123-1133.

Keitz SA, Box TL, Homan RK, Bartlett JA, Oddone EZ. Primary care for patients infected with human immunodeficiency virus. Results of a randomized controlled trial. *Journal of General Internal Medicine* 16:1-10, 2001.

Wellons M, Ottinger J, Weinhold K, Grysowka V, Sanders L, Edwards L, Gooding M, Thomasch, Bartlett JA. Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy. *Journal of Infectious Diseases* 183:1522-1525, 2001.

Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. *AIDS* 15:1369-1377, 2001.

Markert L, Africa P, Alvarez-McLeod, Sempowski G, Hale L, Horvatinovich J, Weinhold K, Bartlett JA, D'Amico T, Haynes B. Thymopoiesis in HIV-infected adults after highly active antiretroviral therapy. *AIDS* 17(17):1635-1643, 2001.

Ortiz G, Wellons M, Brancato J, Vo H, Zinn R, Clarkson D, van Loon K, Bonhoeffer S, Miralles G, Montefiori D,

- Bartlett JA, Nixon D. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. *PNAS* 98(23):13288-13293, 2001.
- Szcech L, Gange S, van der Horst C, Bartlett JA, Young M, Cohen M, Anastos K, Klassen P, Svetkey L. Predictors of proteinuria and renal failure among women with HIV infection. *Kidney International* 61:195, 2002.
- Bartlett JA, Miralles GD, Sevin A, Silberman M, Pruitt S, Ottinger J, Gyszowka, Fiscus S, Bucy P and the ACTG 380 Study Team. Addition of Cyclophosphamide to Antiretroviral Therapy Does Not Diminish the Cellular Reservoir in HIV-infected Persons. *AIDS Res & Human Retroviruses*, 18(8):535-43, 2002.
- Bartlett JA. Addressing the Challenges of Adherence. *J Acquired Immune Deficiency Syndromes* 29:S2-S10, 2002.
- Wellons M, Sanders L, Edwards L, Bartlett JA, Heald A, Schmader K. HIV Infection: Treatment Outcomes in Older and Younger Adults. *J Am Geriatrics Society*, 50(4):603-607, 2002.
- Siraj DS, Bartlett JA, Hyslop N. An Infected Laceration. *Infections in Medicine*, 19:63-65, 2002.
- Szcech L, Edwards L, Sanders L, van der Horst C, Bartlett JA, Heald A, Svetkey L. Protease inhibitors are associated with a slowed progression of HIV-associated renal diseases. *Clinical Nephrology* 57(5):336-41, 2002.
- Schweighardt B, Ortiz G, Grant R, Wellons M, Miralles D, Kostrikis L, Bartlett JA, Nixon D. Emergence of drug resistant HIV-1 variants in subjects undergoing structured treatment interruptions. *AIDS* 16(17):2342-4, 2002.
- Bartlett JA, Tebas P, Bassett R, Huang W, Kuritzkes D, Reisler R, Loyack N, Robison K and the ACTG A5064 Team. Early Intensification with Aabacavir in Subjects at High Risk for Incomplete Viral Suppression. *Antiviral Therapy* 8:361-363; 2003.
- Alexander TH, Ortiz GM, Wellons MF, Allen A, Grace EJ, 2nd, Schweighardt B, et al. Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. *J Acquir Immune Defic Syndr* 34:475-481, 2003.
- Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, Kilby JM, et al. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. *J Infect Dis* 189:1075-1083, 2004.
- Ole-Nguyaine S, Crump JA, Kibiki GS, Kiang K, Taylor J, Schimana W, et al. HIV-associated morbidity, mortality and diagnostic testing opportunities among inpatients at a referral hospital in northern Tanzania. *Ann Trop Med Parasitol* 98:171-179, 2004.
- Sha BE, Onorato M, Bartlett JA, Bosch RJ, Aga E, Nokta M, et al. Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12. *AIDS* 18:1203-1206, 2004.
- Szcech LA, Gange SJ, van der Horst C, Bartlett JA, Young M, Cohen MH, et al. Definition of proteinuria among women with HIV infection. *Kidney Int* 65:1519, 2004.
- Chu HY, Crump JA, Ostermann J, Oenga RB, Itemba DK, Mgonja A, et al. Sociodemographic and clinical characteristics of clients presenting for HIV voluntary counselling and testing in Moshi, Tanzania. *Int J STD AIDS* 16:691-696, 2005.
- Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. *J Infect Dis* 191:825-829, 2005.
- Bartlett JA, Buda JJ, von Scheele B, Mauskopf JA, Davis EA, Elston R, et al. Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview. *J Acquir Immune Defic Syndr* 41:323-331, 2006.
- Thielman NM, Chu HY, Ostermann J, Itemba DK, Mgonja A, Mtwewe S, et al. Cost-effectiveness of free HIV

voluntary counseling and testing through a community-based AIDS service organization in Northern Tanzania. *Am J Public Health* 96:114-119, 2006.

Myers S, Selim A, McDaniel M, Hall R, Zhang Y, Bartlett JA, True A. A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. *Antiviral Therapy* 11:935-939, 2006

Bartlett JA, Johnson J, Herrera G, Sosa N, Rodriguez A, Liao Q, Griffith S, Irlbeck D, Shaefer MS for the CLASS Team. Long Term Results of Initial Therapy with Abacavir and Lamivudine Combined with Efavirenz, Amprenavir/Ritonavir or Stavudine. *J Acquir Immune Defic Syndr* 43(3): 284-292, 2006

Bartlett JA, Fath MJ, DeMasi R, Hermes A, Quinn J, Mondou E, Rousseau Franck. An Updated Systematic Overview of Triple Combination Therapy in Antiretroviral-Naïve HIV-Infected Adults. *AIDS*, 20:2051-2064, 2006

Haas DW, Bartlett JA, Anderson JW, Sanne I, Wilkinson GR, Hinkle J, Rousseau F, Ingram CD, Shaw A, Lederman MM, Kim RB. Pharmacogenetics of Nevirapine-associated Hepatotoxicity: An Adult AIDS Clinical Trials Group Collaboration. *Clinical Infectious Diseases* 43: 783-786, 2006

Fangping C, Chen H, Hicks C, Bartlett J, Zhu J, Gao F. Detection of minor drug-resistant populations by parallel allele-specific sequencing. *Nature Methods* 4:123-125, 2007

Landman KZ, Thielman NM, Mgonja A, Shao HJ, Itemba DK, Ndosi EM, Chu HY, McNeill JD, Shao JF, Bartlett JA, Crump JA. Risk factors for low HIV treatment literacy among clients presenting for voluntary testing and counseling in Moshi, Tanzania. *J Int Assoc Physicians AIDS Care* 6: 24-26, 2007.

Riddler S, Jiang H, Tenorio A, Huang H, Kuritzkes D, Acosta E, Landay A, Bastow B, Haas D, Tashima K, Jain M, Deeks S, Bartlett JA. A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study 5115. *Antiviral Therapy* 12:531-541, 2007.

Morpeth S, Crump J, Shao H, Ramadhani H, Kisenge P, Moylan C, Naggie S, Caram LB, Landman K, Sam N, Itemba D, Shao J, Bartlett J, Thielman N. Predicting CD4 Lymphocyte Count < 200 cells/mm³ in an HIV-1-Infected African Population. *AIDS Research & Human Retroviruses* 23:1230-1236, 2007.

Ramadhani H, Thielman N, Landman K, Ndosi E, Gao F, Kircherr J, Shah R, Shao H, Morpeth S, McNeill J, Shao J, Bartlett J, Crump J. Predictors of incomplete adherence, virologic failure, and viral drug resistance among HIV-1 infected persons receiving antiretroviral therapy in Tanzania. *Clin Inf Dis*: 45:1492-1498, 2007.

Anderson A, Kosinski A, Bartlett J. Declining CD4+ T-cell count during suppressed or low level viremia in patients with HIV infection. *Antiviral Therapy*; 12:1041-1048, 2007.

Bartlett JA, Chen S-S, Quinn J. Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: Results of a systematic overview. *HIV Clinical Trials*; 4:221-226, 2007.

Morpeth S, Thielman N, Ramadhani H, Hamilton J, Ostermann J, Kisenge P, Shao H, Reller LB, Itemba D, Sam N, Bartlett J, Shao J, Crump J. Effect of trimethoprim/sulfamethoxazole prophylaxis on antimicrobial resistance of fecal *Escherichia coli* in HIV-infected patients in Tanzania. *J Acquir Immune Defic Syndr*; 47:585-591, 2008.

Landman K, Ostermann J, Crump J, Mgonja A, Mayhood M, Itemba D, Tribble A, Ndosi E, Chu H, Shao J, Bartlett J, Thielman N. Gender differences in the risk of HIV infection among persons reporting abstinence, monogamy, and multiple sexual partners in northern Tanzania. *PLoS One*; 3:e3705, 2008.

Seshadri C, Uiso LO, Ostermann J, Diefenthal H, Shao HJ, Chu HY, Asmuth DM, Thielman NM, Bartlett JA, Crump JA. Low sensitivity of T-cell based detection of tuberculosis among HIV co-infected Tanzanian inpatients. *East African Med J* 2008; 85: 443-449.

Crump JA, van Ingen J, Morrissey AB, Boeree MJ, Mavura DR, Swai B, Thielman NM, Bartlett JA, Grossman H,

Maro VP, van Soolingen D. Invasive disease caused by nontuberculous mycobacteria, Tanzania. *Emerg Infect Dis* 2009; 15: 53-5.

Tenorio A, Jiang H, Bastow B, Bartlett J, Deeks S, Landay A, Riddler S. Delaying a treatment switch in antiretroviral-treated HIV-1 infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. *AIDS Research & Human Retroviruses*, 2009; 25: 135-139.

Tillekeratne G, Thielman N, Kiwera R, Chu H, Kaale L, Morpeth S, Ostermann J, Mtwewe S, Shao J, Bartlett J, Crump J. High morbidity and mortality in a cohort of HIV-infected adults receiving community home-based care in the Kilimanjaro region, Tanzania, 2003-2005. *Ann Trop Med Parasitol*, 2009; 103:263-73.

Tribble A, Hamilton C, Crump J, Mgonja A, Mtalo A, Ndanu E, Itemba D, Landman K, Ndosi E, Shao J, Bartlett J, Thielman N. Missed Opportunities for Diagnosis of TB-HIV/AIDS Co-infection in Moshi, Tanzania. *Int J TB and Lung Dis* 2009; 7:1260-1266.

Bartlett J, Hornberger J, Sherwade A, Bhor, M, Rajagopalan R. Obstacles and proposed solutions to effective antiretroviral therapy in resource-limited settings. *J Int Assoc Physicians in AIDS Care* 2009; 8:253-268.

Mayhood M, Ostermann J, Crump J, Tribble A, Itemba D, Mgonja A, Mtalo A, Bartlett J, Shao J, Schimana W, Thielman N. Characteristics of HIV voluntary testing and counseling clients before and during care and treatment scale-up in Moshi, Tanzania. *J Acquired Immun Defic Syndr* 2009; 52:648-654.

Bartlett J, Shao J. Success, challenges and limitations of antiretroviral therapy in resource-limited settings. *The Lancet Infectious Diseases* 2009; 9:637-649.

Lofgren S, Morrissey A, Chevalier C, Malabeja A, Edmonds S, Amos B, Sifuna D, Msuya E, von Seidlein L, Schimana W, Stevens W, Bartlett J, Shao J, Crump J. Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote health care facilities. *AIDS* 2009; 23:2459-2466.

Shao H, Crump J, Ramadhani H, Uiso L, Ole-Nguyaine S, Moon A, Kiwera R, Shao J, Bartlett J, Thielman N. Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients co-infected with HIV and tuberculosis in Tanzania. *AIDS Research & Human Retroviruses* 2009; 25:1277-1285.

Szzech L, Menezes P, Quinlivan EB, van der Horst C, Bartlett J, and Svetkey L. Microalbuminuria predicts overt proteinuria among patients with HIV infection. *HIV Medicine* 2009; 11: 419-426.

Emmett S, Cunningham C, Mmbaga B, Kinabo G, Schimana W, Swai M, Bartlett J, Crump J, Reddy E. Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: A cross-sectional study. *J Acquired Immune Def Syndr* 2010; 54: 368-376.

Buchanan A, Muro F, Gratz J, Crump J, Musyoka A, Sichangi, M, Morrissey A, M'rimberia J, Njau B, Msuya L, Bartlett J, Cunningham C. Establishment of hematologic and immunologic reference values for healthy Tanzanian children in the Kilimanjaro region. *Tropical Medicine and International Health* 2010; 15:1011-1021.

Crump J, Ramadhani H, Morrissey A, Saganda W, Mwako M, Yang L-Y, Chow S-C, Morpeth S, Reyburn H, Njau B, Shaw A, Diefenthal H, Shao J, Bartlett J, Maro V. Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected adults and adolescents in northern Tanzania. *Clinical Infectious Diseases* 2011; 52:341-348.

Ostermann J, Reddy E, Shorter M, Muiruri C, Mtalo A, Itemba D, Njau B, Bartlett J, Crump J, Thielman N. Who tests, who doesn't, and why? Uptake of mobile HIV counseling and testing in the Kilimanjaro region of Tanzania. *PLoS One* 2011; 6:e16488.

Waters R, Ostermann J, Reeves T, Masnick M, Thielman N, Bartlett J, Crump J. A cost-effectiveness analysis of

alternative HIV retesting strategies in sub-Saharan Africa. *J Acquired Immune Def Syndr* 2011; 56:443-452.

Crump JA, Ramadhani HO, Morrissey AB, Msuya LJ, Yang L-Y, Chow S-C, Morpeth SC, Reyburn H, Njau BN, Shaw AV, Diefenthal HC, Bartlett JA, Shao JF, Schimana W, Cunningham CK, Kinabo GD. Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected children and infants in northern Tanzania. *Trop Med Int Health* 2011; 16:830-837.

Prabhu M, Nicholson W, Roche A, Kersh G, Fitzpatrick K, Oliver L, Massung R, Morrissey A, Bartlett J, Onyango J, Maro V, Kinabo G, Saganda W, Crump J. Q fever, spotted fever group and typhus group rickettsioses among hospitalized febrile patients in northern Tanzania 2007-2008. *Clinical Infectious Diseases* 2011, 53:e8-15.

Biggs H, Bui D, Galloway R, Stoddard R, Shadomy S, Morrissey A, Bartlett J, Onyango J, Maro V, Kinabo G, Saganda W, Crump J. Leptospirosis among hospitalized patients with febrile illness in northern Tanzania. *Am J Public Health* 2011, 85:275-281.

Vidal A, Murphy S, Hernandez B, Vasquez B, Bartlett J, Oneko O, Overcash F, Smith J, Obure J, Hoyo C. Distribution of HPV genotypes in cervical intraepithelial lesions and cervical cancer in Tanzanian women. *Infectious Agents and Cancer* 2011, 6:20

Kolman M, Decoster M, Proeschold-Bell RJ, Ankeny G, Bartlett J, Sena A. The impact of HIV infections, sexually transmitted diseases and viral hepatitis in Durham County, North Carolina: A call for coordinated and integrated services. *NC Medical Journal* 2012, 72:439-446.

Hertz J, Munishi O, Ooi EE, Shiqin H, Yan LW, Chow A, Morrissey A, Bartlett J, Onyango J, Maro V, Kinabo G, Saganda W, Gubler D, Crump J. Chikungunya and dengue fever among febrile hospitalized patients in northern Tanzania. *Am J Trop Med Hyg* 2012, 86:171-177.

Bartlett J, Ribaud H, Wallis C, Aga E, Katzenstein D, Stevens W, Norton M, Klingman K, Housseinipour M, Crump J, Supparatpinoy K, Badal-Faesen S, Kallungal B, Kumarasamy N. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. *AIDS* 2012, 26:1345-1354.

Crump J, Ramadhani H, Morrissey A, Saganda W, Mwako M, Yang L-Y, Chow S-C, Njau B, Mushi G, Maro V, Reller LB, Bartlett J. Bacteremic disseminated tuberculosis in sub-Saharan Africa: a prospective cohort study. *Clin Inf Dis* 2012; 55:242-250.

Bouley A, Biggs H, Stoddard R, Morrissey A, Bartlett J, Afwamba I, Maro V, Kinabo G, Saganda W, Cleveland S, Crump J. Brucellosis among hospitalized febrile patients in northern Tanzania. *Am J Trop Med & Hyg* 2012; 87:1105-1011.

Nye M, Hoyo C, Huang Z, Vidal A, Wang F, Overcash F, Smith J, Vasquez B, Hernandez B, Swai B, Oneko O, Mlay P, Obure J, Gammon M, Bartlett J, Murphy S. Associations between methylation of paternally expressed gene 3 (PEG3), cervical intraepithelial neoplasia and invasive cervical cancer. *PLoS One* 2013; 8:e56325.

Zullig L, Muiruri C, Abernethy A, Weiner B, Bartlett J, Oneko O, Zafar S. Cancer registration needs assessment at a tertiary medical center in Kilimanjaro, Tanzania. *World Health & Population* 2013; 14:12-23.

Phillips E, Bartlett J, Sanne I, Lederman M, Hinkle J, Rousseau F, Dunn D, Pavlos R, James I, Mallal S, Haas D. Associations between HLA-DRB1*0102, HLA-B*5801 and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. *J Acquired Immune Def Syndr* 2013; 62:e55-57.

Crump J, Morrissey A, Nicholson W, Galloway R, Stoddard R, Ooi EE, Maro V, Sanganda W, Kinabo G, Bartlett J. Etiology of non-malaria fever among hospitalized patients in Northern Tanzania. *PLoS Neg Trop Dis* 2013; 7:e2324.

Fiorillo S, Diefenthal H, Goodman P, Ramadhani H, Njau B, Morrissey A, Mwako M, Bartlett J, Shao J, Saganda W, Kinabo G, Maro V, Crump J. Chest radiograph abnormalities and their role for predicting etiology of febrile

illness among inpatients in Moshi, Tanzania. *Clinical Radiology*, 2013; 68:1039-46.

Mavura D, Masenga EJ, Minja E, Grossmann H, Crump J, Bartlett J. Initiation of antiretroviral therapy in HIV-infected adults with cutaneous manifestations in northern Tanzania. *Internat Journ Dermatology*; 2014; doi: 10.1111/ijd.12563.

Killewo L, Lisasi E, Kapanda G, Tibyampansha D, Ibrahim G, Kulanga A, Muiruri C, Fadhili N, Wiener D, Wood A, Kessi E, Mteta K, Ntabaye M, Bartlett J. Introduction of a learning management system at the Kilimanjaro Christian Medical University College. *African Journal of Health Professions Education*, 2014;6:37-40.

Buchanan A, Dow D, Massambu C, Nyombi B, Shayo A, Musoke R, Feng S, Bartlett J, Cunningham C, Schimana W. Progress in the prevention of mother to child transmission of HIV in three regions of Tanzania. *PLoS One*, 2014; 9:e88679.

Zullig LL, Vanderburg SB, Muiruri C, Abernethy A, Weiner BJ, Bartlett JA, Oneko O, Lisasi E, Munishi OM, Zafar SY. Sustainability of cancer registration in the Kilimanjaro region of Tanzania- A qualitative assessment. *World Health & Population*, 2014;15:21-30.

Nyindo M, Kitau J, Lisasi E, Kapanda G, Matowo J, Francis P, Bartlett J. Introduction of team-based learning (TBL) at Kilimanjaro Christian Medical University College: Experience with the Ectoparasites Module. *Medical Teacher*, 2014;36:308-313.

Harmon JL, Collins-Ogle M, Bartlett J, Thompson J, Barroso J. Integrating routine HIV screening into a primary care setting in rural North Carolina. *Journ Am Assoc Nurses in AIDS Care*, 2014;25:70-82.

Reddy E, Njau B, Morpeth S, Lancaster K, Tribble A, Maro V, Msuya L, Morrissey A, Kibiki G, Thielman N, Cunningham C, Schimana W, Shao J, Chow S-C, Stout J, Crump J, Bartlett J, Hamilton C. High early mortality in a randomized controlled of standard versus intensified tuberculosis diagnostics on treatment decisions by physicians in northern Tanzania. *BMC Infectious Diseases*, 2014;14:89.

Bartz S, Mody A, Kiyimba T, Hornick C, Bain J, Muehlbauer M, Kiboneka E, Stevens R, Bartlett J, St. Peter J, Newgard C, Freemark M. Severe acute malnutrition in childhood: metabolic and hormonal status at presentation, response to treatment, and predictors of mortality. *Journ of Clin Endocrin Metabol*; 2014; <http://dx.doi.org/10.1210/jc.2013-4018>.

Wallis C, Aga E, Ribaud H, Saravanan S, Norton M, Klingman K, Stevens W, Kumarasamy N, Bartlett J, Katzenstein D. Drug susceptibility and resistance mutations after first-line failure in resource-limited settings. *Clin Inf Dis*, 2014; 59: 706-715.

De Boer C, Niyonzima N, Orem J, Bartlett J, Zafar SY. Prognosis and delay of diagnosis among Kaposi's sarcoma patients in Uganda: A cross-sectional study. *Infect Agents and Cancer*, 2014; 9:17.

Lisasi E, Kulanga A, Muiruri C, Killewo L, Fadhili N, Mimano L, Kapanda G, Tibyampansha D, Ibrahim G, Nyindo M, Mteta K, Kessi E, Ntabaye M, Bartlett J. Modernizing and transforming medical education at the Kilimanjaro Christian Medical University College. *Academic Medicine*, 2014; 89:S60-64.

Mody A, Bartz S, Kiyimba T, Bain J, Muehlbauer M, Kiboneka E, Stevens R, St. Peter J, Newgard C, Bartlett J, Freemark M. Effects of HIV infection on metabolic and hormonal status in children with severe acute malnutrition. *PLoS One*; 2014; 9:e102233.

Ramadhani H, Bartlett J, Thielman N, Pence B, Kimani S, Maro V, Mwako M, Masaki L, Mmbando C, Minja M, Lirhunde A, Miller W. Association of first-line antiretroviral therapy adherence with adherence to second-line antiretroviral therapy among HIV-infected patients in Tanzania. *Open Forum Infectious Diseases*, 2014; doi:10.1093/ofid/ofu079.

Rubach M, Maro V, Bartlett J, Crump J. Evaluation of integrated management of adolescent and adult illness district

clinician manual empiric antibiotic therapy recommendations for severe infections in northern Tanzania. *Am J Trop Med Hyg*, 2015; 92:454-462.

Kumarasamy N, Aga E, Ribaldo H, Wallis C, Katzenstein D, Stevens W, Norton M, Klingman K, Bartlett J. Lopinavir/ritonavir monotherapy after virologic failure of first-line NNRTI-containing antiretroviral therapy in resource-limited settings: Week 104 analysis of ACTG A5230. *Clin Inf Dis* 2015; 60:1550-1558.

Vidal A, Skaar D, Maquire R, Dodor S, Musselwhite L, Bartlett J, Oneko O, Obure J, Mlay P, Murphy S, Hoyo C. IL-10, IL-15, IL-17 and GM-CSF levels in cervical cancer tissue of Tanzanian women infected with HPV16/18 vs. non-HPV 16/18 genotypes. *Infectious Agents and Cancer* 2015; 10:10; doi:10.1186/s13027-015-0005-1

Mimano L, Ferrari G, Kapanda G, Lisasi E, Kulanga A, Nyombi B, Muiruri C, Kessi E, Bartlett J, Ntabaye M. Student perceptions on the introduction of training in diagnostic laboratory techniques in an African school of medicine. *MedEdPublish* 2015; <http://dx.doi.org/10.15694/mep.2015.005.0008>

Derache A, Wallis C, Vardanabhuti S, Bartlett J, Katzenstein D. Phenotype, genotype and drug resistance in subtype C HIV-1 infection. *Journ Inf Dis* 2016; 213:250-256.

Ramadhani H, Bartlett J, Thielman N, Pence B, Kimani S, Maro V, Mwako M, Masaki L, Mmbando E, Miller W. The effect of switching to second-line antiretroviral therapy on the risk of opportunistic infections among patients infected with human immunodeficiency virus in northern Tanzania. *Open Forum Infect Dis* 2016; Jan 29;3(1):ofw018. doi: 10.1093/ofid/ofw018. eCollection 2016 Jan.

Kapanda G, Muiruri C, Kulanga A, Tarimo C, Lisasi E, Mimano L, Mteta K, Bartlett J. Enhancing future acceptance of rural placement in Tanzania through peripheral hospital rotations for medical students. *BMC Medical Education*; 16:51doi: 10.1186/s12909-016-0582-8.

Zullig L, Schroeder K, Nyindo P, Namwai T, Silayo E, Moomba A, Munishi M, Karia F, Muiruri C, Bartlett J, Maro V, Zafar Y. Validation and quality assessment of the Kilimanjaro Cancer Registry. *Journ Global Oncology*; doi: 10.1200/JGO.2015.002873.

Borges A, Lundh A, Tendal B, Bartlett J, Clumeck N, Costagliola D, Daar E, Echeverria P, Gisslen M, Huedo-Medina T, Hughes M, Hullseik K, Khabo P, Komati S, Kumar P, Lockman S, MacArthur R, Maggiolo F, Matteeli A, Miro J, Oka S, Petoumenos K, Puls R, Riddler S, Sax P, Sierra-Madero J, Torti C, Lundgren J. Non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based regimens for the initial treatment of HIV infection: a systematic review and meta-analysis of randomized trials. *Clin Inf Dis* 2016; 63:268-280.

Ramadhani H, Muiruri C, Maro V, Omondi M, Mushi J, Lirhunde L, Bartlett J. Association of knowledge on ART line of treatment, scarcity of treatment options and adherence. *BMC Health Services Research* 2016; 16:265 DOI: 10.1186/s12913-016-1483-6.

Vardhanbhuti S, Katzenstein D, Bartlett J, Kumarasamy N, Wallis C. Human immunodeficiency virus-1 sequence changes and drug resistance mutations among virologic failures of lopinavir/ritonavir monotherapy: AIDS Clinical Trials Group Protocol A5230. *Open Forum Inf Dis* 2016; 3 (3): ofw154 doi: 10.1093/ofid/ofw154

Msoka T, Van Guilder G, Smulders Y, van Furth M, Bartlett J, van Agtmael M. Antiretroviral treatment and time since HIV-1 diagnosis are associated with large artery stiffness in sub-Saharan African HIV-1 patients. *Artery Research* 2016; in press.

Matoga M, Hosseinipour M, Aga E, Ribaldo H, Bartlett J, Kumarasamy N, Hughes M and the ACTG A5230 Study Team. Hyperlipidemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings. *Antiviral Therapy* 2016; doi: 10.3851/IMP3101.

2. Chapters in books:

Bartlett JA and Perfect JR. The acquired immune deficiency syndrome. Medicine and Pediatrics; edited by James Crapo: Hanley and Belfus. 1987. Initiation of antiretroviral therapy in HIV-infected adults

McKinney RM, Bartlett JA and Frothingham T. Pediatric infectious diseases. Medicine and Pediatrics; edited by James Crapo: Hanley and Belfus. 1987.

Lyerly HK and Bartlett JA. Thoracic manifestations in the immunocompromised host. Gibbons's Surgery of the Chest; edited by David Sabiston and Frank Spencer: WB Saunders Company. 1989.

Bartlett JA. Chronic management and counseling for persons with HIV infection. Cecil's Textbook of Medicine; edited by Lloyd Smith, Claude Bennett, and James Wyngarden. 1991.

Bartlett JA, Gallis HA, Shipp KW, Nabors KL. Diagnosis and treatment of the patient with HIV infection. Care and Management of Patients with HIV Infection; edited by John A. Bartlett: Clean Data Publishing Co., 1993.

Lyerly HK, DiMiao M and Bartlett JA. Thoracic manifestations in the immunocompromised host. Gibbons's Surgery of the Chest; edited by David Sabiston and Frank Spencer: WB Saunders Company 1994.

Bartlett JA. Chronic management and counseling for persons with HIV infection. Cecil's Textbook of Medicine; edited by Claude Bennett. 1994.

Bartlett JA. Antiretroviral therapy. Caring for Persons with HIV Infection; edited by John A. Bartlett: Clean Data Publishing Co., 1995.

Miralles GD, Bartlett JA. Virology and pathogenesis of HIV. Caring for Persons with HIV Infection; edited by John A. Bartlett: Clean Data Publishing Co., 1997.

Bartlett JA. Zalcitabine. AIDS Therapy; edited by Raphael Dolin, Henry Masur and Michael Saag: Churchill Livingstone, 1997.

Bartlett JA. Management and counseling for persons with HIV infection. Cecil's Textbook of Medicine; edited by Lee Goldman and Claude Bennett. 1999.

Itani S and Bartlett JA. Strategies of Antiretroviral Therapy in Adults. Urologic Clinics of North America 26(4):809-820, ix-x, 1999.

Bartlett JA. Zalcitabine. AIDS Therapy; edited by Raphael Dolin, Henry Masur and Michael Saag: Churchill Livingstone, 2002.

Wellons MF, Bartlett JA. Emetricitabine. AIDS Therapy, edited by Raphael Dolin, Henry Masur and Michael Saag: Churchill Livingstone, 2002.

Bartlett JA. Zalcitabine. AIDS Therapy; edited by Raphael Dolin, Henry Masur and Michael Saag: Churchill Livingstone, 2007.

Muiruri C, Ramadhani H, Bartlett J. Antiretroviral Treat in Resource-limited Settings; edited by Douglas Richman, Thomas Hope and Mario Stevenson: Springer 2015.

3. Books

Bartlett JA. Editor, Caring for Persons with HIV Infection. Clean Data Publishing Co., 1993.

Bartlett JA. Editor, Caring for Persons with HIV Infection. Clean Data Publishing Co., 1996.

Bartlett JA. Editor, *Caring for Persons with HIV Infection*. Clean Data Publishing Co., 1997.

4. Other:

a. Published scientific reviews.

Bartlett JA. HIV Infection: Current and Future Treatment. *Oncology*. 4:19-29, 1990.

Bartlett JA. Current and future treatment of HIV infection. *Primary Care and Cancer*. 11:35-50, 1991.

Bartlett JA. *Clinical Simulation in the Management of HIV Disease*. Medical Age Publishing, 1992.

Bartlett JA. Cryptosporidiosis: Standards of practice. *PAAC Notes* 5:110-112, 1993.

Bartlett JA and Sexton DJ. Decision Making in Medicine: Primary Care of HIV Infection. *Hospital Practice* 53-71, 1998.

Anderson AM, Bartlett JA. Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection. *Expert Rev Anti Infect Ther* 3:871-883, 2005.

Henry K, Bartlett JA, Kojic E, Flanigan TP. Antiretroviral rounds. A communication conundrum. *AIDS Clin Care* 17:115-116, 2005.

Anderson AML, Bartlett JA. Changing Antiretroviral Therapy in the Setting of Virologic Relapse: Review of the Current Literature. *Current HIV/AIDS Reports* 2006; 3:79-85.

Bartlett JA and Muro EP. Generic and branded drugs for the treatment of people living with HIV/AIDS. *J Int Assoc Physicians AIDS Care* 2007; 6:15-23.

Dow D and Bartlett J. Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for treatment of HIV. *Infectious Diseases and Therapy Journal* 2014; 3:83-102

b. Editorials, position and background papers, letters to the editor

Bartlett JA. HIV therapeutics: An emerging science. *Journal of American Medical Association*. 260:3051-3052, 1989.

Bartlett JA. HIV testing in North Carolina. *North Carolina Medical Journal*. 51:150-151, 1990.

Dideriksen P and Bartlett JA. AIDS and Its Metaphors. Book review in *New England Journal of Medicine*. 322:415, 1990.

Shauank S, Albright RE and Bartlett JA. Amplifications of human immunodeficiency virus provirus from cerebrospinal fluid: Results of long-term clinical follow-up. Letter to the editor in *Journal of Infectious Disease*. 164:818, 1991.

Heald AE and Bartlett JA. Cryptosporidium spread in a group residential home. Letter to the editor in *Annals of Internal Medicine*. 6:121; 467-468, 1994.

Keitz SA, Bartlett JA. Facing the challenge of HIV. Primary care physicians have an obligation to care for those infected. *N C Med J* 55:10; 468-470, 1994.

Bartlett JA. The search for an AIDS vaccine: Ethical issues in the development and testing of a preventive AIDS vaccine. Book review in *Journal of Health Care Politics, Policy and Law*. 22:261-263, 1996.

Bartlett JA and Maro VP. Stavudine in first-line antiretroviral regimens in resource-limited settings: time for a better solution. *HIV Therapy* 3:1-3; 2009.

Bartlett JA. Lack of protease inhibitor resistance following treatment failure- too good to be true? *J Clin Invest* 2013; 123:3704-3705.

Jaacks L, Ali M, Bartlett J, Bloomfield G, Checkley W, Gaziano T, Heimbarger D, Kishore S, Kohler R, Lipska K, Manders O, Ngaruiya C, Peck R, Burroughs Pena M, Watkins D, Siegel K, Narayan V. Global Noncommunicable disease research: Opportunities and challenges. *Ann Int Med* 2015; doi: 10.7326/M15-1068.

Kishore S, Bartlett J, Bloomfield G, Heimbarger D, Jaacks L, Lipska K, Ngaruiya C, Peck R, Burroughs Pena M, Siegel K, Manders O, Narayan V, Ali M. The Atlanta Declaration: A twenty-first century vision for US-based global noncommunicable disease research. *Health Affairs Blog*; published September 9, 2015.

Editorial Service:

Ad hoc reviewer *New England Journal of Medicine*, *PLoS Medicine*, *Journal of Infectious Diseases*, *Clinical Infectious Diseases*, *Journal of the American Medical Association*, *Antiviral Therapy*

Section Editor, *Current HIV/AIDS Reports*, March 2007

Editorial Board, *The Open AIDS Journal*, May 2007.

Academic Editor, *PLoS Medicine* November 2007.

Section Editor, *Global/International Health*; *UpToDate Textbook of Medicine*

Consultant appointments:

Primary Infection Committee, NIAID AIDS Clinical Trials Group

Combined Therapies Working Group, NIAID AIDS Clinical Trials Group

Immune Based Therapy Working Group, NIAID AIDS Clinical Trials Group

Expert Panel on HIV Infected Health Care Providers, North Carolina Department of Public Health

Chair, Data and Safety Monitoring Board, Burroughs Wellcome Protocol BW 113:34, 225:03.

Pathogenesis Focus Group, NIAID AIDS Clinical Trials Group

Chair, Treatment Intensification Focus Group, NIAID AIDS Clinical Trials Group

HIV Disease Research Agenda Committee, Adult AIDS Clinical Trials Group

Executive Committee, Adult AIDS Clinical Trials Group

When to Switch Working Group, Adult AIDS Clinical Trials Group

Intermittent Therapy Focus Group, Adult AIDS Clinical Trials Group

Antiviral Advisory Committee, United States Food and Drug Administration

AIDS Immunology and Pathogenesis Study Section, National Institutes of Health

Optimization of Antiretroviral Therapy Research Agenda Committee, AIDS Clinical Trials Group

Vice Chair, Performance Evaluation Committee, AIDS Clinical Trials Group

Executive Committee, Duke University Global Health Institute

Expert Panel on Defining Virologic Failure, World Health Organization

Invited Talks at National and International Meetings:

5th European Conference on Travel Medicine and International Health; Clinical HIV/AIDS in Sub-Saharan Africa: New Findings in a Time of Transition; Amsterdam, Netherlands, May 2007.

47th Interscience Conference on Antimicrobial Agents and Chemotherapy: HIV Infection Among Refugees; Chicago, IL, September 2007.

Professional awards and special recognitions:

Eugene A. Stead, Jr. Teaching Award, 1989

Engel Society, 1990, 2000

Citizen Award, The Independent 1990

The AIDS Community Residence Association Service Award, 1991

Golden Apple Teaching Award, 1992, 1997

Key to the City of Durham from Mayor Sylvia Kerckhoff, 1994

Fellow, American College of Physicians, 1995

Councillor, North Carolina Chapter of the Infectious Diseases Society of America, 1996

Fellow, Infectious Diseases Society of America, 1997

Thomas Kinney Award for Most Outstanding Faculty Member, 1997

Alpha Omega Alpha, 1998

Humanism in Medicine Award, The Healthcare Foundation of New Jersey, 1999

Distinguished Faculty Award, Duke University Medical Alumni Association, 2000

Community Service Award, Durham-Orange County Medical Society, 2000

Donna Davis Community Advocacy Award, Adult AIDS Clinical Trials Group, 2006

Outstanding Achievement Award, North Carolina Community AIDS Fund, 2016

Organizations and participation:

Fellow, American College of Physicians

Member, American Association for the Advancement of Sciences

Member, American Society of Microbiology

Fellow, Infectious Diseases Society of America
Member, International AIDS Society